Abeona Therapeutics Inc (ABEO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Abeona Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 6.40 $ — 71% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 23.2%
- Exp. sales growth 3Y > 5% 381.4%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -48.4%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% 44.7%
- ROCE > 15% -47.1%
- Expected return > 10% -60.2%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 60.2% passed
- More than 10% revenue growth is expected for the coming year 106.0% passed
- Share count grows by less than 3% a year 103.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion 73.7% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 166 m net cash passed
- Operating cash flow covers the profits of the last three years -123 m failed
- Return on capital at 15% or higher, or up versus two years ago -47.1% failed
- Insiders hold at least 10% or are net buyers 16.6% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 208.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.68 | -0.95 – -0.45 | 66 | 44.7% | 3 |
| 12/31/2027 | 0.29 | -0.17 – 0.93 | 135 | 142.0% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.23 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.16 | – | 5 | 69.30 | -194.30 | -17 | -17 |
| 2025: Q1 | -0.21 | – | 0 | – | – | -18 | -20 |
| 2025: Q2 | 1.91 | 1,369.50 | 0 | – | 27,208.20 | -19 | -22 |
| 2025: Q3 | -0.09 | – | 0 | – | – | -21 | -24 |
| 2025: Q4 | -0.36 | – | 5 | 13.30 | -377.50 | -18 | -19 |
| 2026: Q1 | -0.30 | – | 9 | – | -195.80 | -20 | -21 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1 | -24 | -22 | -16.00 | -13 | 99 | 111 |
| 2017 | 1 | -28 | -27 | -16.41 | -23 | 170 | 179 |
| 2018 | 3 | -58 | -57 | -29.81 | -39 | 134 | 174 |
| 2019 | 0 | -77 | -76 | -37.88 | -63 | 178 | 223 |
| 2020 | 10 | -81 | -84 | -22.72 | -35 | 103 | 151 |
| 2021 | 3 | -90 | -85 | -21.57 | -66 | 42 | 80 |
| 2022 | 1 | -51 | -40 | -5.05 | -43 | 27 | 64 |
| 2023 | 4 | -47 | -54 | -2.53 | -37 | 15 | 64 |
| 2024 | 0 | -64 | -64 | -1.55 | -56 | 44 | 109 |
| 2025 | 6 | -89 | 71 | 1.08 | -76 | 159 | 220 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Abeona Therapeutics Inc., ein biopharmazeutisches Unternehmen in der Vermarktungsphase, entwickelt Gen- und Zelltherapien für lebensbedrohliche Erkrankungen in den USA.
| Employees | 226 |
|---|---|
| Headquarters | Cleveland, OH |
| Address | 6555 Carnegie Avenue, 44103 Cleveland, United States |
| Phone | 646 813 4701 |
| Website | abeonatherapeutics.com |
| IPO Date | 19. Sep 1980 |
| ISIN | US00289Y2063 |
| Stock Split | 1:25 on 07/05/2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director | 1976 |
| Joseph Walter Vazzano CPA | Chief Financial Officer | 1984 |
| Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer | 1969 |
| Brian Kevany Ph.D. | Chief Technical & Scientific Officer | – |
| Gregory Gin | Vice President of Investor Relations & Corporate Communications | – |
| Gianine Esposito | Senior VP & Chief People Officer | – |
| Jon Voss | VP & Head of Quality | 1960 |
| Madhav Vasanthavada M.B.A., Ph.D. | SVP, Chief Commercial Officer & Head of Business Development | 1979 |
| Carl Denny | Senior Vice President of Regulatory Affairs | – |
| Megan Callan | Vice President & Head of Quality | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 21. Jul 2026 | Vazzano Joseph Walter | Chief Financial Officer | Sell | 1,478 | 6.53 | 9,651 |
| 9. Jul 2026 | Vazzano Joseph Walter | Chief Financial Officer | Sell | 24,880 | 6.96 | 173,257 |
| 9. Jul 2026 | Seshadri Vishwas | Chief Executive Officer | Sell | 67,971 | 6.96 | 473,330 |
| 9. Jul 2026 | O'Malley Brendan M. | SVP, Chief Legal Officer | Sell | 12,050 | 6.96 | 83,913 |
| 9. Jul 2026 | Vasanthavada Madhav | Chief Commercial Officer | Sell | 12,606 | 6.96 | 87,784 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.